Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: In vitro and in vivo evaluation

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2366-2378

  Rawat, Manoj K ^a   Jain, Achint ^a   Singh, Sanjay ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Bioavailability; Biodegradable; First pass metabolism; Intestinal lymphatic route; Lipids; Morphology; Nanoparticles; Oral absorption; Particle size; Stability

Indexed keywords

LIPID; PHOSPHATIDYLCHOLINE; POLOXAMER; REPAGLINIDE; SOLID LIPID NANOPARTICLE; STEARIC ACID; TRISTEARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; GLUCOSE BLOOD LEVEL; INTESTINE FLUID; MALE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; RAT; SOLID STATE; STOMACH JUICE; STREPTOZOCIN DIABETES; SURFACE PROPERTY; TRIACYLGLYCEROL BLOOD LEVEL; ZETA POTENTIAL;

EID: 79954481926     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22435     Document Type: Article

References (44)

1. O'Driscoll CM. 2002. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 15:405-415.
2. Bargoni R, Cavalli O, Caputo A, Fundaro MR, Gasco, Zara GP. 1998. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 15:745-750.
3. Vyas SP, Jaitely V, Kanaujia P. 1999. Synthesis and characterization of palmitoyl propranolol hydrochloride auto-lymphotrophs for oral administration. Int J Pharm 186:177-189.
4. Muhlen AZ, Mehnert W. 1998. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 53:2-55.
5. Porter CJ, Charman WN. 2001. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev 50:S127-S147.
6. Hussain N, Jaitley V, Florence AT. 2001. Recent advances in the understanding of uptake of microparticulate across the gastrointestinal lymphatics. Adv Drug Deliv Rev 50:107-142.
7. Sarmento B, Susana M, Domingos F, Eliana SB. 2007. Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomed 2:743-749.
8. Zara GP, Bargoni A, Cavalli R, Fundaro A, Vighetto D, Gasco MR. 2002. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 91:1324-1333.
9. Manjunath K, Venkateswarlu V. 2006. Pharmacokinetics, tissue distribution, and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target 14:632-645.
10. Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, Mehta A, Vyas SP. 2009. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 5:184-191.
11. Luo YF, Chen DW, Ren LX. 2006. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 114:53-59.
12. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. 2009. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133:238-244.
13. Mehnert W, Mader K. 2001. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47:165-196.
14. Manjunath K, Reddy JS, Venkateswarlu V. 2005. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 27:127-144.
15. Windbergs M, Strachan CJ, Kleinebudde P. 2009. Understanding the solid-state behaviour of triglyceride solid lipid extrudates and its influence on dissolution. Eur J Pharm Biopharm 71:80-87.
16. Jenning V, Gohla S. 2000. Comparison of wax and glycerides solid lipid nanoparticles. Int J Pharm 196:219-222.
17. Mayer-Davis EJ, Levin S, Bergman RN. 2001. Insulin secretion, obesity, and potential behavioral influences: results from the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Metab Res Rev 17:137-145.
18. Muthu MS, Singh S. 2008. Studies on biodegradable polymeric nanoparticles of risperidone: In vitro and in vivo evaluation. Nanomedicine 2:233-240.
19. US. Pharmacopeia. XXIV, 2006. Vol. USP 29. Rockville, MD.
20. Holm R, Mullertz A, Christensen E, Hoy CE. 2001. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur J Pharm Sci 14:331-337.
21. Verger ML, Fluckiger L, Kim Y. 1998. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 46:137-143.
22. Singh S, Muthu MS. 2007. Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. Nanomedicine 3:305-319.
23. Moneghini M, Volinovich D, Princivalle F. 2000. Formulation and evaluation of vinypyrrolidone/vinylacetate copolymer microspheres with carbamazepine. Pharm Dev Technol 5:347-353.
24. Kim A, Yun MO, Oh YK, Ahn WS, Kim CK. 1999. Pharmacodynamics of insulin in polyethylene glycol-coated liposomes. Int J Pharm 180:75-81.
25. Lu Y, Zhang Y, Yang Z, Tang X. 2009. Formulation of an intravenous emulsion loaded with clarithromycin-phospholipid complex and its pharmacokinetics in rats. Int J Pharm 366:160-169.
26. Goldberg IJ, Isaacsa A, Sehayekb E, Breslowb JL, Huanga LS. 2004. Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice. Atherosclerosis 172:47-53.
27. Adikwu MU, Yoshikawa Y, Takada K. 2004. Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. Biomaterials 25:3041-3048.
28. Bunjes H, Westesen K, Koch MHJ. 1996. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 129:159-173.
29. Jenning V, Thunemann AF, Gohla SH. 2000. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199:167-177.
30. Westesen K, Bunjes H, Koch MJH 1997. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 48: 223-236.
31. Gisele A, Castro Lucas A, Ferreira M. 2008. Characterization of a new solid lipid nanoparticle formulation containing retinoic acid for topical treatment of acne. Powder Diffr 23:S31-S35.
32. Olbrich C, Muller RH. 1999. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm 180:31-39.
33. Garcia-Fuentes M, Torres D, Alonso MJ. 2003. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloid Surf B Biointerfaces 27:159-68.
34. Roger E, Lagarce F, Benoit JP. 2009. The gastrointestinal stability of lipid nanocapsules. Int J Pharm 379:260-265.
35. Muller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 50:161-177.
36. Wissing SA, Kayser O, Muller RH. 2004. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257-1272.
37. Kumar VV, Chandrasekar D, Ramakrishna S. 2007. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glycerid lipids on plasma pharmacokinetics. Int J Pharm 335:167-175.
38. Hu FQ, Jiang SP, Du YZ. 2005. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 45:167-173.
39. Betancourt T, Brown B, Brannon-Peppas L. 2007. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: Preparation, characterization and in vitro evaluation. Nanomedicine 2:219-232.
40. Mansbach CM, Nevin P. 1998. Intracellular movement of triacylglycerols in intestine. J Lipid Res 39:963-968.
41. Cavalli R, Bargoni A, Podio V, Muntoni E. 2003. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 92:1085-1094.
42. Nordskog BK, Phan CT, Nutting DF, Tso P. 2001. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv Drug Deliv Rev 50:21-44.
43. Ros E. 2000. Intestinal absorption of triglyceride and cholesterol, dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 151:357-379.
44. Mullar RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto, EB 2006.Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 317:82-89.